A NOVEL APPROACH TO
AIRWAY DISEASES
Find out more about our unique therapeutic strategy
Our non-antibiotic macrolide platform addresses epithelial dysfunction and other key drivers of inflammation in chronic respiratory diseases.
Tackling one of the world's most prevalent diseases
Chronic obstructive pulmonary disease (COPD) afflicts more than a quarter of a billion people globally, leading to more than 3 million deaths every year.
The unmet need for disease-modifying therapies for COPD
There are no clinical trials showing that any existing medications for COPD modify the long-term decline in lung function that characterizes COPD.
A new paradigm of epithelial barrier insufficiency
Find out more about our unique approach targeting epithelial barrier insufficiency as a key driver of inflammation in chronic respiratory diseases.
LATEST NEWS
CONTACT US
SEND US A MESSAGE